MX370481B - Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. - Google Patents

Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos.

Info

Publication number
MX370481B
MX370481B MX2017012736A MX2017012736A MX370481B MX 370481 B MX370481 B MX 370481B MX 2017012736 A MX2017012736 A MX 2017012736A MX 2017012736 A MX2017012736 A MX 2017012736A MX 370481 B MX370481 B MX 370481B
Authority
MX
Mexico
Prior art keywords
vectors containing
clones
signal sequence
polya signal
productivity
Prior art date
Application number
MX2017012736A
Other languages
English (en)
Inventor
Knoetgen Hendrik
Michael Huelsmann Peter
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX370481B publication Critical patent/MX370481B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente se reporta que para transfecciones transitorias el uso del promotor alfa de factor 1 de elongación humano (con el intrón A) proporciona una productividad mejorada (en organización de LC-HC-SM), el uso de la secuencia de señal poliA de hormona del crecimiento bovina proporciona una productividad mejorada en comparación con el uso de la secuencia de señal poliA de SV40, la adición de hGT a la secuencia de señal poliA de bGH resulta en una productividad aumentada en vectores que contienen el promotor hCMV y la organización de vector CL (3'-5')-HC-SM resulta en expresión mejorada. Para acumulados estables se reporta que acumulados generados con vectores que contienen el promotor a de hEF1 muestran una productividad mejorada en análisis por lotes, clones generados con los vectores que contienen el promotor hEF1a muestran un número reducido de clones poco productores, y los clones generados con vectores que contienen el promotor hEF1a muestran una mayor estabilidad de expresión de IgG. Para clones únicos se reporta que la organización del vector con la posición corriente abajo del marcador de selección (LC-HC-SM) tiene un efecto positivo sobre la productividad de clones únicos y que los clones generados con vectores que contienen la secuencia de señal poliA de bGH y hGT tienen las mayores productividades.
MX2017012736A 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos. MX370481B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11195361 2011-12-22
PCT/EP2012/076203 WO2013092743A2 (en) 2011-12-22 2012-12-19 Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides

Publications (1)

Publication Number Publication Date
MX370481B true MX370481B (es) 2019-12-16

Family

ID=47504950

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014007359A MX355624B (es) 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
MX2017012736A MX370481B (es) 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresión, métodos novedosos de generación de células de producción y su uso para la producción recombinante de polipéptidos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014007359A MX355624B (es) 2011-12-22 2012-12-19 Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.

Country Status (14)

Country Link
US (2) US20160208284A1 (es)
EP (2) EP2794651B1 (es)
JP (4) JP6096802B2 (es)
KR (4) KR102166824B1 (es)
CN (4) CN113881702B (es)
BR (1) BR112014014239B1 (es)
CA (2) CA3149402A1 (es)
ES (1) ES2930215T3 (es)
HR (1) HRP20221383T1 (es)
MX (2) MX355624B (es)
PL (1) PL2794651T3 (es)
RU (2) RU2756910C2 (es)
SG (3) SG10201900915WA (es)
WO (1) WO2013092743A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2756910C2 (ru) * 2011-12-22 2021-10-06 Ф. Хоффманн-Ля Рош Аг Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
WO2015053523A1 (ko) * 2013-10-07 2015-04-16 한화케미칼 주식회사 항체 발현용 바이시스트로닉 발현벡터 및 이를 이용한 항체의 생산 방법
CN105255867A (zh) * 2015-10-19 2016-01-20 北京益生合生物科技有限公司 一种防止启动子在传代培养中逐渐灭活的基因序列及其应用
US11261462B2 (en) 2016-01-27 2022-03-01 Just-Evotec Biologics, Inc. Inducible expression from transposon-based vectors and uses
WO2017132376A1 (en) 2016-01-27 2017-08-03 Just Biotherapeutics, Inc. Hybrid promoter and uses thereof
US11098310B2 (en) 2016-01-27 2021-08-24 Just-Evotec Biologics, Inc. Expression from transposon-based vectors and uses
CN110022904B (zh) 2016-10-20 2024-04-19 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
WO2018211529A1 (en) * 2017-05-19 2018-11-22 Council Of Scientific & Industrial Research A method for producing refolded recombinant humanized ranibizumab
JP7081139B2 (ja) * 2017-12-20 2022-06-07 東ソー株式会社 新規プロモーターおよびそれを含む発現ベクター
JP2022501036A (ja) * 2018-09-20 2022-01-06 サノフイSanofi イントロンベースの普遍的なクローニング方法および組成物
EP3856910B1 (en) 2018-09-24 2024-11-20 Merck Sharp & Dohme LLC Expression vectors for eukaryotic expression systems
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
KR20210134932A (ko) 2019-03-29 2021-11-11 에프. 호프만-라 로슈 아게 정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 FcRn 발현 세포를 생성하는 방법
KR102798616B1 (ko) 2019-12-20 2025-04-22 (주)셀트리온 목적 단백질의 고발현을 위한 인트론을 포함하는 발현 카세트 및 이의 이용
CN116981774A (zh) * 2021-01-12 2023-10-31 Jcr制药股份有限公司 整合有编码配体与具有生理活性的蛋白质的融合蛋白的基因的核酸分子
TW202237657A (zh) 2021-01-29 2022-10-01 美商默沙東藥廠 計畫性死亡受體1(pd-1)抗體之組合物及獲得該組合物之方法
US20240252619A1 (en) * 2021-05-21 2024-08-01 The Regents Of The University Of California Coronavirus Constructs and Vaccines
CN118525094A (zh) * 2023-05-23 2024-08-20 西安佑佰生物科技有限公司 一种增强相邻启动子转录活性的载体及其方法
KR102640929B1 (ko) 2023-06-02 2024-02-27 (주) 멥스젠 미세생체조직시스템 형성 장치

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3584341D1 (de) 1984-08-24 1991-11-14 Upjohn Co Rekombinante dna-verbindungen und expression von polypeptiden wie tpa.
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
JP3051411B2 (ja) 1989-03-14 2000-06-12 持田製薬株式会社 新規ｄｎａならびにそれを含有する発現プラスミド
US5266491A (en) 1989-03-14 1993-11-30 Mochida Pharmaceutical Co., Ltd. DNA fragment and expression plasmid containing the DNA fragment
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
RU2201449C2 (ru) * 1994-10-14 2003-03-27 Сембайозис Дженетикс Инк. Слитый полипептид, способный к целенаправленному переносу к масляному телу, химерная днк-контрукция, экспрессирующая кассета
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
DE69840412D1 (de) 1997-10-31 2009-02-12 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
PT1222292E (pt) 1999-10-04 2005-11-30 Medicago Inc Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
KR100408844B1 (ko) 2000-07-29 2003-12-06 한국산업기술평가원 동물세포 발현벡터
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
NZ581474A (en) 2001-08-03 2011-04-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
KR100988949B1 (ko) 2001-10-25 2010-10-20 제넨테크, 인크. 당단백질 조성물
EP1308517A1 (en) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vectors for expressing multiple transgenes
DE60230918D1 (de) * 2001-11-16 2009-03-05 Biogen Idec Inc Polycistronische expression von antikörpern in cho zellen
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
EP1502603A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk AN ANTIBODY COMPOSITION CONTAINING MEDICAMENT FOR PATIENTS WITH Fc gamma RIIIa POLYMORPHISM
CA2481837A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
AU2003236017B2 (en) 2002-04-09 2009-03-26 Kyowa Kirin Co., Ltd. Drug containing antibody composition
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
CN100383244C (zh) * 2003-01-07 2008-04-23 西福根有限公司 用于生产重组多克隆蛋白质的方法
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
JPWO2005035778A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法
PT1692182E (pt) 2003-11-05 2010-05-13 Roche Glycart Ag Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
CN101001953B (zh) * 2004-06-17 2013-03-13 惠氏公司 具有三个完整转录单元的质粒和用于诱导hiv免疫反应的免疫原性组合物
JP4860702B2 (ja) * 2005-10-21 2012-01-25 エフ．ホフマン−ラ ロシュ アーゲー ポリペプチドのリコンビナント発現のための方法
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20080124760A1 (en) * 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
DK2059533T3 (da) 2006-08-30 2013-02-25 Genentech Inc Multispecifikke antistoffer
US20100015627A1 (en) * 2006-12-22 2010-01-21 Vincent Beuger Selection method
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008121324A2 (en) * 2007-03-30 2008-10-09 Abbott Laboratories Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
ATE535607T1 (de) * 2007-06-29 2011-12-15 Hoffmann La Roche Promotor
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
AU2009286956B2 (en) * 2008-08-28 2012-12-06 Novartis Ag Cell surface display of polypeptide isoforms by stop codon readthrough
GB0903207D0 (en) * 2009-02-25 2009-04-08 Ucb Pharma Sa Method for expressing multimeric proteins
BRPI1014089A2 (pt) 2009-04-02 2016-04-19 Roche Glycart Ag anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
RU2756910C2 (ru) * 2011-12-22 2021-10-06 Ф. Хоффманн-Ля Рош Аг Комбинации элементов экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов

Also Published As

Publication number Publication date
MX2014007359A (es) 2014-08-01
JP6096802B2 (ja) 2017-03-15
JP2015500656A (ja) 2015-01-08
RU2017140661A (ru) 2019-02-12
EP2794651B1 (en) 2022-09-21
SG10201700169PA (en) 2017-02-27
HRP20221383T1 (hr) 2023-01-06
CA2854249C (en) 2022-05-03
CA2854249A1 (en) 2013-06-27
WO2013092743A3 (en) 2013-10-03
ES2930215T3 (es) 2022-12-07
RU2017140661A3 (es) 2021-08-09
MX355624B (es) 2018-04-25
US20210024952A1 (en) 2021-01-28
EP3354660A1 (en) 2018-08-01
KR20190132702A (ko) 2019-11-28
RU2756910C2 (ru) 2021-10-06
HK1200848A1 (en) 2015-08-14
CN113881702A (zh) 2022-01-04
JP2020054372A (ja) 2020-04-09
CN113881702B (zh) 2025-05-30
CN104011075B (zh) 2017-06-06
BR112014014239B1 (pt) 2021-10-13
KR20210031002A (ko) 2021-03-18
CN104011075A (zh) 2014-08-27
RU2014129727A (ru) 2016-02-20
KR102048556B1 (ko) 2019-11-26
JP6417436B2 (ja) 2018-11-07
PL2794651T3 (pl) 2022-12-27
EP2794651A2 (en) 2014-10-29
SG10201900915WA (en) 2019-03-28
KR102166824B1 (ko) 2020-10-19
KR20140106585A (ko) 2014-09-03
WO2013092743A2 (en) 2013-06-27
CN113896787A (zh) 2022-01-07
BR112014014239A2 (pt) 2017-12-26
KR20200032240A (ko) 2020-03-25
SG11201403443WA (en) 2014-07-30
CN107119073A (zh) 2017-09-01
RU2639519C2 (ru) 2017-12-21
JP2017108753A (ja) 2017-06-22
US20160208284A1 (en) 2016-07-21
KR102229491B1 (ko) 2021-03-18
KR102285184B1 (ko) 2021-08-03
JP7096806B2 (ja) 2022-07-06
JP2019030311A (ja) 2019-02-28
CA3149402A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
MX355624B (es) Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos.
FI3536797T3 (fi) Siirtogeenin tehostettu ilmentäminen ja prosessointi
UA129709C2 (uk) ПОЛІПЕПТИД З ПРОТЕАЗНОЮ АКТИВНІСТЮ IdeS
NZ609959A (en) Modified factor ix polypeptides and uses thereof
WO2016092550A3 (en) Methods of producing long acting ctp-modified polypeptides
RU2016116847A (ru) Животные с гуманизированным геном il-15
EP4624490A3 (en) Modified fc region of antibody
RU2013143303A (ru) FcγRIIb-СПЕЦИФИЧНОЕ Fc-АНТИТЕЛО
MX2011013183A (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
MX2015012450A (es) Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
MX2009012747A (es) Produccion de proteina recombinante en celulas ebx de aves.
MX2015012361A (es) Metodos de fabricacion para controlar el contenido de lisina c-terminal, galactosa y acido sialico en proteinas recombinantes.
MX370861B (es) Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la producción de factor de crecimiento del nervio beta.
MX371007B (es) Vectores de expresión que comprenden un promotor de citomegalovirus quimérico y secuencias mejoradoras.
MX2012013232A (es) Analogos de hormona paratiroidea y usos para los mismos.
HRP20200744T1 (hr) Organizacija ekspresijskog vektora, novi postupci generiranja proizvodnje stanica i njihova uporaba za rekombinantnu proizvodnju polipeptida
WO2007003582A3 (en) Serum-free stable transfection and production of recombinant human proteins in human cell lines
MX365947B (es) Operaciones de cosecha mejoradas para proteinas recombinadas.
EA201490958A1 (ru) Засухоустойчивые растения, полученные путем модификации генного локуса stgx, ответственного за фенотип оставаться зеленым
JP2017524366A5 (es)
MX2014003508A (es) Vectores basados en el virus de la tristeza de los cítricos para la expresion de gen/es ajenos.
PH12015502224A1 (en) Polypeptide glycosylated with sialylated sugar chain
MX352229B (es) Metodo de produccion de polipeptido recombinante.
MX2015013842A (es) Metodos y constructos para expresar proteinas biologicamente activas en celulas de mamifero.
MY166974A (en) Anti-human epo receptor antibodies and method of use